Crizotinib and ceritinib trigger immunogenic cell death via on-target effects
Immunogenic cell death (ICD) has initially been discovered in the context of chemotherapy. High-dose crizotinib also stimulates ICD, as we described for non-small cell lung cancer lacking activating chromosomal aberrations of ALK or ROS1, the usual targets of crizotinib, indicating that crizotinib m...
Guardado en:
Autores principales: | Adriana Petrazzuolo, Maria Perez-Lanzon, Peng Liu, M. Chiara Maiuri, Guido Kroemer |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Taylor & Francis Group
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/e23c9a7cc4f4489bbcbe3bcb80d2149b |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Clinicopathological and prognostic implications of ALK rearrangement in patients with completely surgically resected lung adenocarcinoma
por: Huan Zhang, et al.
Publicado: (2021) -
Linfoma anaplástico de células grandes CD30 positivo cutáneo primario: reporte de un caso
por: Navarrete-Dechent,Cristián, et al.
Publicado: (2015) -
Defining Pathological Activities of ALK in Neuroblastoma, a Neural Crest-Derived Cancer
por: Anna M. Wulf, et al.
Publicado: (2021) -
Driver oncogenes in Sub-Saharan African patients with non-small cell lung cancer
por: Legius B, et al.
Publicado: (2016) -
Hexokinases II‐mediated glycolysis governs susceptibility to crizotinib in ALK‐positive non‐small cell lung cancer
por: Caiyu Lin, et al.
Publicado: (2021)